Biocon Launches Yesafili , Biosimilar Aflibercept, in the US
Biocon Limited launched Yesafili , a biosimilar aflibercept, in the United States on August 3, 2026. Approved as an interchangeable biosimilar to Eylea 2 mg by the U.S. FDA in May 2024, it treats eye conditions like AMD and DME. This launch expands Biocon's ophthalmology presence.
The launch of a biosimilar in the US market, particularly for a drug with significant sales like Eylea , is expected to have a notable impact on Biocon's revenue and market share in the ophthalmology segment. The product addresses a condition affecting millions in the US, indicating potential for substantial uptake.
The announcement details the successful commercial launch of a new biosimilar product in a major market (United States), which is a positive development for the company's business growth and patient access to medicines.
Biocon Limited has announced the commercial launch of Yesafili™ (aflibercept-jbvf) in the United States on August 3, 2026. Yesafili™ is an interchangeable biosimilar to Regeneron's Eylea® 2 mg, indicated for treating neovascular age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
The U.S. Food and Drug Administration (FDA) previously approved the product and granted it interchangeable designation in May 2024. This allows for substitution at the pharmacy level, potentially increasing patient access to this critical treatment.
The launch is a significant step for Biocon in expanding the global availability of biosimilar aflibercept, particularly in the ophthalmology segment. The company highlighted that an estimated 19.8 million Americans live with AMD, and the U.S. sales of aflibercept reached approximately $5.89 billion in 2023, indicating a substantial market need.
Data from the Phase 3 INSIGHT Study demonstrated no clinically meaningful differences between Yesafili™ and Eylea® 2 mg in terms of pharmacokinetics, safety, efficacy, and immunogenicity. Biocon has provided comprehensive analytical, nonclinical, and clinical data to support the biosimilarity of Yesafili™ to its reference product.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.